NHGRI logo

Implicating Sequence Variants in Human Disease

On September 12-13, 2012, the National Human Genome Research Institute (NHGRI), sponsored a workshop - Implicating Sequence Variants in Human Disease - at the Hyatt Regency Bethesda, in Bethesda, Md. Teri Manolio, M.D., Ph.D., NHGRI, and Daniel MacArthur, Ph.D., Massachusetts General Hospital, co-chaired the workshop. The goal of the workshop was to develop guidelines for investigators, reviewers and editors to consider in assessing the evidence implicating sequence variants or genes as causal in a specific disease.

 

Wednesday, September 12, 2012

  Topic Speaker
1 Welcome and Introductions
Video		 Daniel MacArthur, Ph.D.
Massachusetts General Hospital
2 The Need for Criteria to Implicate DNA Variants: Real-World Examples
Video | Slides		 Mark Daly, Ph.D.
Massachusetts General Hospital
3 Maintaining Accurate Information in Variant Databases
Video | Slides		 Heidi Rehm, Ph.D., F.A.C.M.G
Partners Healthcare
4 Laboratory Perspectives on Variant Implication David Dimmock, M.D.
Medical College of Wisconsin
5 Discussion
Video		 All Participants

 

Thursday, September 13, 2012

  Topic Speaker
6 Revisions (as needed) to Plans for Day's Discussions
Video		 Daniel MacArthur, Ph.D.
Massachusetts General Hospital
START OF WORKGROUP DISCUSSIONS
7 Study Design: What sample selection and data processing procedures maximize power and minimize false positives in identifying causal variants?
Video | Slides		 Study Design Workgroup:
  • Jeffrey Barrett, Ph.D.
  • Nancy Cox, Ph.D.
  • Teri Manolio, M.D., Ph.D.
  • Benjamin Voight, Ph.D.
8 Statistical Analysis: How can we robustly identify variants underlying disease?
Video | Slides		 Statistical Analysis Workgroup:
  • Suzanne Leal, Ph.D.
  • Goncalo Abecasis, D.Phil.
  • Joel Hirschhorn, M.D., Ph.D.
  • Daniel MacArthur, Ph.D
9 Known Variants: Which candidate causal variants/genes in a patient or cohort have been previously implicated in similar phenotypes?
Video | Slides		 Known Variants Workgroup:
  • David Goldstein, Ph.D.
  • Russ Altman, M.D., Ph.D.
  • Leslie Biesecker, M.D.
  • Heidi Rehm, Ph.D., F.A.C.M.G.
10 Estimating Impact: How can we predict the variants most likely to have an effect on biological function?
Video		 Estimating Impact Workgroup:
  • Greg Cooper, Ph.D.
  • Stylianos Antonarakis, M.D., Sc.D.
  • Shamil Sunyaev, Ph.D.
  • Daniel MacArthur, Ph.D.
11 Experimental Data: How can we investigate whether candidate causal variants have a biological effect on disease risk?
Video | Slides		 Experimental Data Workgroup:
  • Wendy Winckler, Ph.D.
  • Len Pennacchio, Ph.D.
  • Jay Shendure, M.D., Ph.D.
  • John Stamatoyannopoulos, M.D., Ph.D.
12 Clinical Implications: How could these guidelines be used in context of diagnostic-decision-making?
Video | Slides		 Clinical Implications Workgroup:
  • David Adams, M.D., Ph.D.
  • Euan Ashley, M.R.C.P., D.Phil
  • David Dimmock, M.D.
  • David Valle, M.D.
13 Integrated Approach: How can we sum across different classes of evidence to assess overall confidence in variant causality?
Video | Slides		 Integrated Approach Workgroup:
  • Mark Daly, Ph.D.
  • Don Conrad, Ph.D.
  • Mark Gerstein, Ph.D.
  • Chris Gunter, Ph.D.
END OF WORKGROUP DISCUSSIONS
14 Outline of White Paper / Summary of Key Messages and Next Steps
Video		 Daniel MacArthur, Ph.D.
Massachusetts General Hospital

Teri Manolio, M.D., Ph.D.
National Human Genome Research Institute

 

Last updated: September 12, 2012